BioSenic S.A. and its subsidiary Medsenic SAS announces the promotion of Dr. Carole Nicco to Chief Operating Officer (COO) in addition to her position as Chief Scientific Officer (CSO). Dr. Carole Nicco will be involved in the strategic planning, decision-making and management of key initiatives, as well as overseeing and enhancing the strategic development of BioSenic's pipelines, targeting treatments with its visco supplementation, cell therapy and arsenic trioxide platforms. She will work closely with BioSenic's CEO, Prof. François Rieger, to further oversee and enhance BioSenic's strategic decisions. Dr. Nicco has already begun to meet and interact with key global players interested in the development of the global BioSenic project or targeted therapeutic innovations.

BioSenic wishes her all due success in her new commitments in company.